FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Essetifin SPA 		2. Issuer Name and Ticker or Trading Symbol

SOLIGENIX, INC. [ SNGX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
_____ Officer (give title below)      __ X __ Other (specify below)
Former 10% Owner
(Last)          (First)          (Middle)

VIA SUDAFRICA, 20 		3. Date of Earliest Transaction (MM/DD/YYYY)

11/29/2017
(Street)

ROME, L6 00144
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   11/29/2017     S    271140   (1) D $2.12   0   (2) (3) I   (3) (6) Indirect   (3)
Common Stock   11/29/2017     P    271140   (1) A $2.12   271140   (2) (3) D   (3) (6)  
Common Stock   11/29/2017     S    5954   (1) D $2.12   0   (4) I   (4) (6) Indirect   (4)
Common Stock   11/29/2017     P    5954   (1) A $2.12   277094   (4) D   (4) (6)  
Common Stock   11/29/2017     S    16416   (1) D $2.12   0   (5) I   (5) (6) Indirect   (5)
Common Stock   11/29/2017     P    16416   (1) A $2.12   293510   (5) D   (5) (6)  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split.
(2)  This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer.
(3)  Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock.
(4)  Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin.
(5)  Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin.
(6)  Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein.

Remarks:
Exhibit List: Exhibit 24.1 - Power of Attorney; Exhibit 99.1 - Joint Filers' Signatures

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Essetifin SPA
VIA SUDAFRICA, 20
ROME, L6 00144


Former 10% Owner
CAVAZZA PAOLO
VIA TESSERETE, 10
LUGANO, V8 00000


Former 10% Owner
Leadiant Biosciences, Inc.
9841 WASHINGTONIAN BLVD., SUITE 500
GAITHERSBURG, MD 20878


Former 10% Owner
Cavazza Enrico
VIA SUDAFRICA, 20
ROME, L6 00144


Former 10% Owner
Cavazza Francesca
VIA SUDAFRICA, 20
ROME, L6 00144


Former 10% Owner
Cavazza Silvia
VIA SUDAFRICA, 20
ROME, L6 00144


Former 10% Owner
Cavazza Preta Martina
VIA SUDAFRICA, 20
ROME, L6 00144


Former 10% Owner

Signatures
Essetifin S.p.A. By: /s/ Marino Zigrossi 11/30/2017
** Signature of Reporting Person Date

/s/ Fabio Poma for Paolo Cavazza by power of attorney 11/30/2017
** Signature of Reporting Person Date

Leadiant Biosciences, Inc. By: /s/ Marino Zigrossi 11/30/2017
** Signature of Reporting Person Date

/s/ Marino Zigrossi for Enrico Cavazza by power of attorney 11/30/2017
** Signature of Reporting Person Date

/s/ Marino Zigrossi for Francesca Cavazza by power of attorney 11/30/2017
** Signature of Reporting Person Date

/s/ Marino Zigrossi for Silvia Cavazza by power of attorney 11/30/2017
** Signature of Reporting Person Date

/s/ Marino Zigrossi for Martina Cavazza Preta by power of attorney 11/30/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Soligenix Charts.
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Soligenix Charts.